KLRK1 and graft versus host disease: To this point, as NKG2D activating ligands are not expressed on healthy cells, this may also reduce instances of graft-versus-host disease (GVHD) following administration of adoptive cell therapies, thus maintaining potent antitumor activity while limiting off-target toxicity (92).